No significant benefit of moderate-dose vitamin C on severe COVID-19 cases

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Nutritional Science

Background:

• No specific antiviral drug exists for COVID-19.
• Investigating potential treatments like vitamin C is crucial for severe cases.
• Vitamin C has antioxidant and anti-inflammatory properties that may be beneficial.

Purpose of the Study:

• To evaluate the clinical efficacy of moderate-dose intravenous vitamin C in severe COVID-19 inpatients.
• To determine if vitamin C impacts mortality or clinical improvement.
• To provide evidence-based insights for managing severe COVID-19.

Main Methods:

• Retrospective analysis of 397 severe COVID-19 patients admitted between February 13-29, 2020.
• Comparison between patients receiving standard therapy plus intravenous vitamin C (2-4 g/day) and those receiving standard therapy alone.
• Inverse Probability Treatment Weighting (IPTW) analysis to control for confounding factors.

Main Results:

• No significant association was found between vitamin C use and all-cause death (weighted HR, 2.69; 95% CI, 0.91-7.89).
• Clinical improvement occurred in 74.3% of the vitamin C group versus 95.1% in the control group, with no significant difference observed (weighted HR, 0.76; 95% CI, 0.55-1.07).
• Moderate-dose intravenous vitamin C showed no significant benefit in reducing death risk or improving clinical outcomes.

Conclusions:

• Moderate-dose intravenous vitamin C administration did not demonstrate significant clinical efficacy in severe COVID-19 patients.
• The findings suggest that vitamin C infusion may not be a beneficial adjunctive therapy for severe COVID-19.
• Further research may be needed to explore vitamin C's role in different COVID-19 stages or dosages.